Regulus Therapeutics Inc. (RGLS) financial statements (2021 and earlier)

Company profile

Business Address 10628 SCIENCE CENTER DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:3134146076114160
Cash and cash equivalents31341414151637
Short-term investments   476198122
Other undisclosed cash, cash equivalents, and short-term investments   0   
Restricted cash and investments     1 
Receivables      0
Prepaid expense34456  
Other current assets     1 
Other undisclosed current assets22126185
Total current assets:3740196787134165
Noncurrent Assets
Property, plant and equipment 18101254
Intangible assets, net (including goodwill)0011111
Intangible assets, net (excluding goodwill)0011111
Deferred costs      1
Other noncurrent assets0001002
Other undisclosed noncurrent assets0     (1)
Total noncurrent assets:129111377
TOTAL ASSETS:38422878101141171
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3471314119
Accounts payable1126632
Accrued liabilities1145664
Employee-related liabilities2222222
Deferred revenue 0
Debt5151720   
Deferred revenue and credits0013
Contract with customer, liability3
Other liabilities33     
Other undisclosed current liabilities1     23
Total current liabilities:12222733141335
Noncurrent Liabilities
Liabilities, other than long-term debt 00101145
Deferred revenue and credits101124
Contract with customer, liability0
Other liabilities 00 021
Other undisclosed noncurrent liabilities  7 20 (1)
Total noncurrent liabilities: 07103144
Total liabilities:12223443451739
Stockholders' equity
Stockholders' equity attributable to parent, including:2620(6)3556124132
Common stock0000000
Additional paid in capital453431387381329316268
Accumulated other comprehensive loss   (0)(0)(0)(0)
Accumulated deficit(427)(411)(393)(346)(273)(192)(136)
Other undisclosed stockholders' equity attributable to parent00     
Total stockholders' equity:2620(6)3556124132
TOTAL LIABILITIES AND EQUITY:38422878101141171

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:107001218
Operating expenses(24)(24)(47)(70)(83)(76)(53)
Operating loss:(14)(17)(47)(70)(82)(55)(45)
Nonoperating expense
(Investment Income, Nonoperating)
     (2)(12)
Interest and debt expense(2)(2)(2)(3)(1)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(16)(19)(49)(73)(83)(57)(57)
Other undisclosed income from continuing operations before income taxes0001110
Loss from continuing operations before income taxes:(16)(19)(49)(72)(82)(56)(57)
Income tax expense (benefit) (0)(0)000(0)
Net loss available to common stockholders, diluted:(16)(19)(49)(72)(82)(56)(57)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(16)(19)(49)(72)(82)(56)(57)
Comprehensive loss:(16)(19)(49)(72)(82)(56)(57)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent   (0)00(0)
Comprehensive loss, net of tax, attributable to parent:(16)(19)(49)(72)(82)(56)(57)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: